CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.72B, above the global median of $1.15B
- FinancialsHigh earnings quality
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.72BUSDvs all stocks (USD)
Trailing P/E
255.91xvs Biotechnology peers
Revenue (TTM)
769.10MUSDvs all stocks (USD)
Profit Margin
6.16%vs Biotechnology peers
Beta
0.4640xvs all stocks
52-Week Change
29.09%vs all stocks
Market Capitalization
9.72BUSDvs all stocks (USD)
Enterprise Value
9.29BUSDvs all stocks (USD)
Trailing P/E
255.91xvs Biotechnology peers
Forward P/E
27.93xvs Biotechnology peers
PEG Ratio
-0.9923xvs Biotechnology peers
Price to Sales (TTM)
12.50xvs Biotechnology peers
Price to Book (MRQ)
15.07xvs Biotechnology peers
Enterprise to Revenue
12.07xvs Biotechnology peers
Gross Margin
98.25%vs Biotechnology peers
Profit Margin
6.16%vs Biotechnology peers
Operating Margin
-30.08%vs Biotechnology peers
Return on Assets (TTM)
-0.62%vs Biotechnology peers
Return on Equity (TTM)
7.17%vs Biotechnology peers
Revenue (TTM)
769.10MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.40USDUpdated Jul 18, 2026Quarterly Revenue Growth
4.90%vs Biotechnology peers
Gross Profit (TTM)
755.64MUSDvs all stocks (USD)
EBITDA (TTM)
46.69MUSDvs all stocks (USD)
Net Income (TTM)
46.68MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.89%vs Biotechnology peers
Operating Cash Flow (TTM)
120.45MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
115.66MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
761.41MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
12.98MUSDFY2025 · Dec 31, 2025Gross Profit
748.43MUSDFY2025 · Dec 31, 2025Operating Income
44.80MUSDvs all stocks (USD)
Pre-tax Income
66.46MUSDFY2025 · Dec 31, 2025Income Tax Expense
-33.19MUSDFY2025 · Dec 31, 2025Net Income
99.65MUSDFY2025 · Dec 31, 2025EBIT
44.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
46.69MUSDFY2025 · Dec 31, 2025Research & Development
254.91MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
448.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.67MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.9500USDFY2025 · Dec 31, 2025EPS (Diluted)
0.8200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
103.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
103.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
99.65MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
1.48MUSDFY2025 · Dec 31, 2025Operating Cash Flow
160.91MUSDFY2025 · Dec 31, 2025Free Cash Flow
160.70MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.89M of depreciation against 211K of capital expenditure, and its own free-cash-flow line reads 141.79M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
120.50MUSDFY2025 · Dec 31, 2025Income Tax Paid
12.97MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
99.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.89MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-37.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
84.50MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
25.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.85MUSDFY2025 · Dec 31, 2025Capital Expenditures
-211.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-319.61MUSDFY2025 · Dec 31, 2025Sale of Investments
389.58MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
69.76MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-72.94MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-72.94MUSDFY2025 · Dec 31, 2025Shares Outstanding
107.33MSharesUpdated Jul 18, 2026Float Shares
89.94MSharesUpdated Jul 18, 2026Shares Short
8.64MSharesUpdated Jul 18, 2026Short Ratio
8.57daysvs all stocks
Short % of Shares Outstanding
10.39%vs all stocks
% Held by Insiders
11.54%vs all stocks
% Held by Institutions
75.56%vs all stocks
Total Cash (MRQ)
338.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.15USDUpdated Jul 18, 2026Total Debt (MRQ)
9.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0151xvs Biotechnology peers
Current Ratio (MRQ)
2.86xvs Biotechnology peers
Book Value per Share (MRQ)
5.94USDUpdated Jul 18, 2026Total Assets
836.65MUSDvs all stocks (USD)
Total Current Assets
485.46MUSDFY2025 · Dec 31, 2025Total Liabilities
188.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
351.19MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
22.76MUSDFY2025 · Dec 31, 2025Total Current Liabilities
166.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
120.50MUSDFY2025 · Dec 31, 2025Other Short-term Investments
251.66MUSDFY2025 · Dec 31, 2025Accounts Receivable
59.79MUSDFY2025 · Dec 31, 2025Inventory
12.87MUSDFY2025 · Dec 31, 2025Accounts Payable
40.44MUSDFY2025 · Dec 31, 2025Short-term Debt
1.08MUSDFY2025 · Dec 31, 2025Deferred Revenue
35.68MUSDFY2025 · Dec 31, 2025Other Current Liabilities
6.91MUSDFY2025 · Dec 31, 2025Long-term Debt
5.02MUSDFY2025 · Dec 31, 2025Common Stock (Book)
140.00KUSDFY2025 · Dec 31, 2025Retained Earnings
643.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
647.80MUSDvs all stocks (USD)
Treasury Stock
966.59MUSDFY2025 · Dec 31, 202552-Week Low
28.66USDUpdated Jul 18, 202652-Week High
95.11USDUpdated Jul 18, 202652-Week Change
29.09%vs all stocks
Beta
0.4640xvs all stocks
50-Day MA
73.43USDUpdated Jul 18, 2026200-Day MA
61.05USDUpdated Jul 18, 2026Avg 10-Day Volume
1.09MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.03MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
0.3500USDUpdated Jul 18, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
It has bought back shares for years, and its equity earns more than its industry and yields heavy free cash flow.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.98Profit Margin: 0.06
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.72B, above the global median of $1.15BNotable
Market cap (USD): 9,717,466,288Global Median: 1,146,734,693.424
Revenue is $769.1M, above the global median of $520.53MNotable
Revenue (USD): 769,096,000Global Median: 520,528,949.311
Levered free cash flow is $115.66M, above the global median of $16.24MNotable
Levered free cash flow (USD): 115,660,496Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
SJS Enterprises Ltd.
7 interpretationsHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Garmin Ltd.
7 interpretationsHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
XPEL, Inc.
7 interpretationsHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover